UK probes mega AstraZeneca deal for US biotech firm Alexion

(Alliance News) - Britain's competition watchdog on Tuesday said it was investigating the planned ...

Alliance News 25 May, 2021 | 3:26PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Britain's competition watchdog on Tuesday said it was investigating the planned purchase of US biotech company Alexion Pharmaceuticals Inc by Covid-19 vaccine-maker AstraZeneca PLC in a deal worth USD39 billion.

In a brief statement, the Competition & Markets Authority said it was looking at whether the deal would "result in a substantial lessening of competition within any market or markets in the UK for goods or services".

The planned tie-up, aimed at boosting AstraZeneca's work on immunology, was announced in December as the London-listed company began to roll out the coronavirus vaccine it developed with the University of Oxford.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 8,357.00 GBX 1.10
Alexion Pharmaceuticals Inc

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement